ArticleApplied biochemistry and biotechnology2025
Astragalus Polysaccharides Alleviate Lumbar Disc Herniation by Promoting the O-GlcNAcylation of NRF2.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lumbar disc herniation (LDH) is a complex degenerative disease caused by inflammation and mechanical compression of nerve roots by the nucleus pulposus (NP). Astragalus polysaccharides (APS) have anti-inflammatory and immunomodulatory effects. Given the regulatory role of O-GlcNAcylation in inflammation and degenerative diseases, this study aimed to explore the potential molecular regulatory mechanism of O-GlcNAcylation in the anti-inflammatory effect of APS in LDH. We established the LDH rat model to investigate the effects of APS on LDH and inflammatory response. IL-1β-stimulated NP cells were generated, and inflammation was assessed by measuring the expression of IL-6, IL-18, and TNF-α with enzyme-linked immunosorbent assay. The apoptosis of NP cells was analyzed by flow cytometry. The underlying mechanism was investigated by quantitative real-time PCR, co-immunoprecipitation, and molecular docking. The results indicated that APS inhibited proinflammatory cytokine expression in LDH rats and IL-1β-induced NP cells. APS bonded to OGT and promoted its mediated-O-GlcNAcylation levels. Further, we certified that NRF2 was the target of OGT-mediated O-GlcNAcylation. Of note, the silencing of NRF2 abolished the protective effects of OGT on IL-1β-stimulated NP cells. The mitigation effect of APS on LDH is through enhancing OGT expression to promote O-GlcNAcylation of NRF2, suggesting that O-GlcNAcylation of NRF2 is an important regulatory factor for LDH and offers a novel treatment strategy for the disease.
Indexed as
Identifiers
41082001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.